Literature DB >> 30721982

Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.

Min Z Levine1, Emily T Martin2, Joshua G Petrie2, Adam S Lauring3, Crystal Holiday1, Stacie Jefferson1, William J Fitzsimmons3, Emileigh Johnson2, Jill M Ferdinands1, Arnold S Monto2.   

Abstract

BACKGROUND: Influenza vaccine effectiveness was low in 2017-2018, yet circulating influenza A(H3N2) viruses were antigenically similar to cell-grown vaccine strains. Notably, most influenza vaccines are egg propagated.
METHODS: Serum specimens were collected shortly after illness onset from 15 influenza A(H3N2) virus-infected cases and 15 uninfected hospitalized adults. Geometric mean titers against egg- and cell-grown influenza A/Hong Kong/4801/2014(H3N2) virus vaccine strains and representative circulating viruses (including A/Washington/16/2017) were determined by a microneutralization (MN) assay. Independent effects of strain-specific titers on susceptibility were estimated by logistic regression.
RESULTS: MN titers against egg-grown influenza A/Hong Kong virus were significantly higher among vaccinated individuals (173 vs 41; P = 0.01). In unadjusted models, a 2-fold increase in titers against egg-grown influenza A/Hong Kong virus was not significantly protective (29% reduction; P = .09), but a similar increase in the cell-grown influenza A/Washington virus antibody titer (3C.2a2) was protective (60% reduction; P = .02). Higher egg-grown influenza A/Hong Kong virus titers were not significantly associated with infection, when adjusted for antibody titers against influenza A/Washington virus (15% reduction; P = .61). A 54% reduction in the odds of infection was observed with a 2-fold increase in titer against influenza A/Washington virus (P = not significant), adjusted for the titer against egg-grown influenza A/Hong Kong virus titer.
CONCLUSION: Individuals vaccinated in 2017-2018 had high antibody titers against the egg-adapted vaccine strain and lower titers against circulating viruses. Titers against circulating but not egg-adapted strains were correlated with protection.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Influenza A; antibodies; egg adaptation; vaccine effectiveness

Mesh:

Substances:

Year:  2019        PMID: 30721982      PMCID: PMC6534188          DOI: 10.1093/infdis/jiz049

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  MUSCLE: multiple sequence alignment with high accuracy and high throughput.

Authors:  Robert C Edgar
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

2.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.

Authors:  Yao-Qing Chen; Teddy John Wohlbold; Nai-Ying Zheng; Min Huang; Yunping Huang; Karlynn E Neu; Jiwon Lee; Hongquan Wan; Karla Thatcher Rojas; Ericka Kirkpatrick; Carole Henry; Anna-Karin E Palm; Christopher T Stamper; Linda Yu-Ling Lan; David J Topham; John Treanor; Jens Wrammert; Rafi Ahmed; Maryna C Eichelberger; George Georgiou; Florian Krammer; Patrick C Wilson
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

3.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Authors:  Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto
Journal:  Vaccine       Date:  2019-02-07       Impact factor: 3.641

Review 4.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.

Authors:  Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean
Journal:  Lancet Infect Dis       Date:  2016-04-06       Impact factor: 25.071

5.  Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Authors:  Sharon Frey; Timo Vesikari; Agnieszka Szymczakiewicz-Multanowska; Maria Lattanzi; Allen Izu; Nicola Groth; Sandra Holmes
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

6.  Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells.

Authors:  F Liaini Gross; Yaohui Bai; Stacie Jefferson; Crystal Holiday; Min Z Levine
Journal:  J Vis Exp       Date:  2017-11-22       Impact factor: 1.355

7.  nextflu: real-time tracking of seasonal influenza virus evolution in humans.

Authors:  Richard A Neher; Trevor Bedford
Journal:  Bioinformatics       Date:  2015-06-26       Impact factor: 6.937

8.  AliView: a fast and lightweight alignment viewer and editor for large datasets.

Authors:  Anders Larsson
Journal:  Bioinformatics       Date:  2014-08-05       Impact factor: 6.937

9.  Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Authors:  Brendan Flannery; Richard K Zimmerman; Larisa V Gubareva; Rebecca J Garten; Jessie R Chung; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Suzanne E Ohmit; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Pedro A Piedra; Vasiliy P Mishin; Anton P Chesnokov; Sarah Spencer; Swathi N Thaker; John R Barnes; Angie Foust; Wendy Sessions; Xiyan Xu; Jacqueline Katz; Alicia M Fry
Journal:  J Infect Dis       Date:  2016-05-06       Impact factor: 7.759

10.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

View more
  9 in total

1.  Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.

Authors:  Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons.

Authors:  Constantina Boikos; Ian McGovern; Deborah Molrine; Justin R Ortiz; Joan Puig-Barberà; Mendel Haag
Journal:  Vaccines (Basel)       Date:  2022-06-03

Review 3.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

4.  Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.

Authors:  Sigrid Gouma; Seth J Zost; Kaela Parkhouse; Angela Branche; David J Topham; Sarah Cobey; Scott E Hensley
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

5.  Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Emily T Martin; Caroline Cheng; Joshua G Petrie; Elif Alyanak; Manjusha Gaglani; Donald B Middleton; Shekhar Ghamande; Fernanda P Silveira; Kempapura Murthy; Richard K Zimmerman; Arnold S Monto; Christopher Trabue; H Keipp Talbot; Jill M Ferdinands
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

6.  Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin.

Authors:  Juhye M Lee; Rachel Eguia; Seth J Zost; Saket Choudhary; Patrick C Wilson; Trevor Bedford; Terry Stevens-Ayers; Michael Boeckh; Aeron C Hurt; Seema S Lakdawala; Scott E Hensley; Jesse D Bloom
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

7.  Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.

Authors:  Vivek Shinde; Rongman Cai; Joyce Plested; Iksung Cho; Jamie Fiske; Xuan Pham; Mingzhu Zhu; Shane Cloney-Clark; Nan Wang; Haixia Zhou; Bin Zhou; Nita Patel; Michael J Massare; Amy Fix; Michelle Spindler; David Nigel Thomas; Gale Smith; Louis Fries; Gregory M Glenn
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

8.  Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults.

Authors:  Kailey Hughes; Donald B Middleton; Mary Patricia Nowalk; Goundappa K Balasubramani; Emily T Martin; Manjusha Gaglani; H Keipp Talbot; Manish M Patel; Jill M Ferdinands; Richard K Zimmerman; Fernanda P Silveira
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

9.  Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity.

Authors:  Ming Xia; Md Rejaul Hoq; Pengwei Huang; Wen Jiang; Xi Jiang; Ming Tan
Journal:  Nano Res       Date:  2022-01-28       Impact factor: 10.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.